ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2022, Vol. 36 ›› Issue (3): 20-29.doi: 10.6040/j.issn.1673-3770.0.2021.561
Previous Articles Next Articles
YAO Shuang1,2Overview,LOU Hongfei3,4
CLC Number:
| [1] Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe: an underestimated disease. A GA2LEN study[J]. Allergy, 2011, 66(9): 1216-1223. doi:10.1111/j.1398-9995.2011.02646.x. [2] Sedaghat AR, Kuan EC, Scadding GK. Epidemiology of chronic rhinosinusitis: prevalence and risk factors[J]. J Allergy Clin Immunol Pract, 2022, S2213-S2198(22):00032-0. doi:10.1016/j.jaip.2022.01.016. [3] Pilan RR, Pinna FR, Bezerra TF, et al. Prevalence of chronic rhinosinusitis in Sao Paulo[J]. Rhinology, 2012, 50(2): 129-138. doi:10.4193/Rhino11.256. [4] Shi JB, Fu QL, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities[J]. Allergy, 2015, 70(5): 533-539. doi:10.1111/all.12577. [5] Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011[J]. Allergy, 2016, 71(8): 1170-1180. doi:10.1111/all.12874. [6] Castillo Vizuete JA, Sastre J, del Cuvillo Bernal A, et al. Asthma, rhinitis, and nasal polyp multimorbidities[J]. Arch Bronconeumol(Engl Ed), 2019, 55(3): 146-155. doi:10.1016/j.arbres.2018.09.001. [7] Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease[J]. J Allergy Clin Immunol Pract, 2017, 5(4): 1061-1070.e3. doi:10.1016/j.jaip.2016.12.027. [8] Lee WH, Kim JW, Lim JS, et al. Chronic rhinosinusitis increases the risk of hemorrhagic and ischemic stroke: a longitudinal follow-up study using a national sample cohort[J]. PLoS One, 2018, 13(3): e0193886. doi:10.1371/journal.pone.0193886. [9] Bhattacharyya N. Associations between obesity and inflammatory sinonasal disorders[J]. Laryngoscope, 2013, 123(8): 1840-1844. doi:10.1002/lary.24019. [10] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(Suppl S29): 1-464. doi:10.4193/Rhin20.600. [11] National C,Promising I. The National Academies Collection: Reports funded by National Institutes of Health [M]. Washington(DC): National Academies Press(US)Copyright © 2011, National Academy of Sciences, 2011. [12] Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease[J]. Lancet, 2008, 372(9643): 1107-1119. doi:10.1016/S0140-6736(08)61452-X. [13] Lou HF, Meng YF, Piao YS, et al. Cellular phenotyping of chronic rhinosinusitis with nasal polyps[J]. Rhinology, 2016, 54(2): 150-159. doi:10.4193/Rhino15.271. [14] Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese[J]. J Allergy Clin Immunol, 2009, 124(3): 478-484, 484.e1-2. doi:10.1016/j.jaci.2009.05.017. [15] Lou HF, Meng YF, Piao YS, et al. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population[J]. Am J Rhinol Allergy, 2015, 29(5): 350-356. doi:10.2500/ajra.2015.29.4231. [16] Huvenne W, van Bruaene N, Zhang N, et al. Chronic rhinosinusitis with and without nasal polyps: what is the difference?[J]. Curr Allergy Asthma Rep, 2009, 9(3): 213-220. doi:10.1007/s11882-009-0031-4. [17] Zhang N, van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease[J]. J Allergy Clin Immunol, 2008, 122(5): 961-968. doi:10.1016/j.jaci.2008.07.008. [18] Wang XD, Zhang N, Bo MY, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania[J]. J Allergy Clin Immunol, 2016, 138(5): 1344-1353. doi:10.1016/j.jaci.2016.05.041. [19] 李华斌, 赖玉婷, 姜文秀. 慢性鼻窦炎的内表型研究进展及精准治疗[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 9-13. doi:10.6040/j.issn.1673-3770.0.2018.043. LI Huabin, LAI Yuting, JIANG Wenxiu. Endotypes and precision medicine in chronic sinusitis treatment[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 9-13.doi:10.6040/j.issn.1673-3770.0.2018.043. [20] Sejima T, Holtappels G, Kikuchi H, et al. Cytokine profiles in Japanese patients with chronic rhinosinusitis[J]. Allergol Int, 2012, 61(1): 115-122. doi:10.2332/allergolint.10-OA-0290. [21] Yu JQ, Xian M, Piao YS, et al. Changes in clinical and histological characteristics of nasal polyps in Northern China over the past 2-3 decades[J]. Int Arch Allergy Immunol, 2021, 182(7): 615-624. doi:10.1159/000513312. [22] Lou HF, Wang CS, Zhang L. Endotype-driven precision medicine in chronic rhinosinusitis[J]. Expert Rev Clin Immunol, 2019, 15(11): 1171-1183. doi:10.1080/1744666X.2020.1679626. [23] Katotomichelakis M, Tantilipikorn P, Holtappels G, et al. Inflammatory patterns in upper airway disease in the same geographical area may change over time[J]. Am J Rhinol Allergy, 2013, 27(5): 354-360. doi:10.2500/ajra.2013.27.3922. [24] Kim SJ, Lee KH, Kim SW, et al. Changes in histological features of nasal polyps in a Korean population over a 17-year period[J]. Otolaryngol Head Neck Surg, 2013, 149(3): 431-437. doi:10.1177/0194599813495363. [25] van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators[J]. Allergy, 2006, 61(11): 1280-1289. doi:10.1111/j.1398-9995.2006.01225.x. [26] Klingler AI, Stevens WW, Tan BK, et al. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps[J]. J Allergy Clin Immunol, 2021, 147(4): 1306-1317. doi:10.1016/j.jaci.2020.11.037. [27] Cao PP, Wang ZC, Schleimer RP, et al. Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes[J]. Ann Allergy Asthma Immunol, 2019, 122(1): 33-40. doi:10.1016/j.anai.2018.10.014. [28] Kato A, Peters AT, Stevens WW, et al. Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches[J]. Allergy, 2022, 77(3): 812-826. doi:10.1111/all.15074. [29] Xu ZF, Huang YR, Delemarre T, et al. Advances in chronic rhinosinusitis in 2020 and 2021[J]. J Allergy Clin Immunol, 2022, 149(3): 854-866. doi:10.1016/j.jaci.2021.12.782. [30] Tomassen P, Vandeplas G, van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers[J]. J Allergy Clin Immunol, 2016, 137(5): 1449-1456.e4. doi:10.1016/j.jaci.2015.12.1324. [31] Wei B, Liu F, Zhang J, et al. Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a Chinese population[J]. Rhinology, 2018, 56(3): 216-226. doi:10.4193/Rhin17.240. [32] Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes[J]. Allergy, 2018, 73(7): 1459-1469. doi:10.1111/all.13411. [33] Staudacher AG, Peters AT, Kato A, et al. Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis[J]. Ann Allergy Asthma Immunol, 2020, 124(4): 318-325. doi:10.1016/j.anai.2020.01.013. [34] Yao Y, Zeng M, Liu Z. Revisiting Asian chronic rhinosinusitis in the era of type 2 biologics[J]. Clin Exp Allergy, 2022, 52(2): 231-243. doi:10.1111/cea.14065. [35] Delemarre T, Bochner BS, Simon HU, et al. Rethinking neutrophils and eosinophils in chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2021, 148(2): 327-335. doi:10.1016/j.jaci.2021.03.024. [36] Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois[J]. J Allergy Clin Immunol, 2017, 139(2): 699-703.e7. doi:10.1016/j.jaci.2016.06.063. [37] Delemarre T, Holtappels G, de Ruyck N, et al. Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype[J]. J Allergy Clin Immunol, 2020, 146(2): 337-343.e6. doi:10.1016/j.jaci.2020.04.040. [38] Ray A, Kolls JK. Neutrophilic inflammation in asthma and association with disease severity[J]. Trends Immunol, 2017, 38(12): 942-954. doi:10.1016/j.it.2017.07.003. [39] Schleimer RP, Freeland HS, Peters SP, et al. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils[J]. J Pharmacol Exp Ther, 1989, 250(2): 598-605. [40] Banuelos J, Lu NZ. A gradient of glucocorticoid sensitivity among helper T cell cytokines[J]. Cytokine Growth Factor Rev, 2016, 31: 27-35. doi:10.1016/j.cytogfr.2016.05.002. [41] Wu D, Yan B, Wang Y, et al. Charcot-Leyden crystal concentration in nasal secretions predicts clinical response to glucocorticoids in patients with chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2019, 144(1): 345-348.e8. doi:10.1016/j.jaci.2019.03.029. [42] Wallwork B, Coman W, Mackay-Sim A, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis[J]. Laryngoscope, 2006, 116(2): 189-193. doi:10.1097/01.mlg.0000191560.53555.08. [43] Zeng M, Wang H, Liao B, et al. Clinical and biological markers predict the efficacy of glucocorticoid- and macrolide-based postoperative therapy in patients with chronic rhinosinusitis[J]. Am J Rhinol Allergy, 2021, 35(5): 596-606. doi:10.1177/1945892420982236. [44] Strehl C, Ehlers L, Gaber T, et al. Glucocorticoids-all-rounders tackling the versatile players of the immune system[J]. Front Immunol, 2019, 10: 1744. doi:10.3389/fimmu.2019.01744. [45] Wu D, Yan B, Wang Y, et al. Prognostic and pharmacologic value of cystatin SN for chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2021, 148(2): 450-460. doi:10.1016/j.jaci.2021.01.036. [46] Wu D, Yan B, Wang Y, et al. Predictive significance of Charcot-Leyden crystal protein in nasal secretions in recurrent chronic rhinosinusitis with nasal polyps[J]. Int Arch Allergy Immunol, 2021, 182(1): 65-75. doi:10.1159/000510120. [47] 史剑波, 孙悦奇, 许庚. 基于内在型的慢性鼻窦炎手术治疗策略[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 130-135. doi:10.3760/cma.j.cn115330-20210819-00561. SHI Jianbo, SUN Yueqi, XU Geng. Endotype-based surgical treatment of chronic rhinosinusitis[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(2): 130-135. doi:10.3760/cma.j.cn115330-20210819-00561. [48] Snidvongs K, Kalish L, Sacks R, et al. Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis[J]. Am J Rhinol Allergy, 2013, 27(3): 221-233. doi:10.2500/ajra.2013.27.3880. [49] Zhang L, Zhang Y, Gao Y, et al. Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma[J]. Rhinology, 2020, 58(2): 126-135. doi:10.4193/Rhin19.184. [50] Alsharif S, Jonstam K, van Zele T, et al. Endoscopic sinus surgery for type-2 CRS wNP: an endotype-based retrospective study[J]. Laryngoscope, 2019, 129(6): 1286-1292. doi:10.1002/lary.27815. [51] 刘争, 曾明. 加强国人慢性鼻窦炎内在型研究 推进精准诊疗[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 99-105. doi:10.3760/cma.j.cn115330-20210830-00581. LIU Zheng, ZENG Ming. Promoting the research of endotypes of Chinese patients with chronic rhinosinusitis and facilitating precision medicine[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(2): 99-105. doi:10.3760/cma.j.cn115330-20210830-00581. [52] Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial[J]. JAMA, 2016, 315(5): 469-479. doi:10.1001/jama.2015.19330. [53] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(liberty np sinus-24 and liberty np sinus-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet, 2019, 394(10209): 1638-1650. doi:10.1016/S0140-6736(19)31881-1. [54] Fujieda S, Matsune S, Takeno S, et al. The effect of dupilumab on intractable chronic rhinosinusitis with nasal polyps in Japan[J]. Laryngoscope, 2021, 131(6): E1770-E1777. doi:10.1002/lary.29230. [55] 姚银, 曾明, 刘争. 慢性鼻窦炎伴鼻息肉的生物靶向治疗[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 231-236. doi:10.3760/cma.j.cn115330-20210901-00586. YAO Yin, ZENG Ming, LIU Zheng. Biologics in chronic rhinosinusitis with nasal polyps[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(2): 231-236. doi:10.3760/cma.j.cn115330-20210901-00586. [56] Cheraghlou S, Cohen JM. Early adoption of dupilumab in the medicare population in 2017[J]. Yale J Biol Med, 2020, 93(5): 675-677. [57] Patel GB, Peters AT. The role of biologics in chronic rhinosinusitis with nasal polyps[J]. Ear Nose Throat J, 2021, 100(1): 44-47. doi:10.1177/0145561320964653. [58] Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date[J]. Ther Clin Risk Manag, 2020, 16: 31-37. doi:10.2147/TCRM.S210648. [59] Chang TW, Davis FM, Sun NC, et al. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases[J]. Biotechnology(N Y), 1990, 8(2): 122-126. doi:10.1038/nbt0290-122. [60] Gevaert P, Calus L, van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma[J]. J Allergy Clin Immunol, 2013, 131(1): 110-116.e1. doi:10.1016/j.jaci.2012.07.047. [61] Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils[J]. J Allergy Clin Immunol, 2004, 113(2): 297-302. doi:10.1016/j.jaci.2003.11.044. [62] Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials[J]. J Allergy Clin Immunol, 2020, 146(3): 595-605. doi:10.1016/j.jaci.2020.05.032. [63] 申珅, 娄鸿飞, 闫冰, 等. 抗IgE单克隆抗体治疗合并哮喘的复发性慢性鼻窦炎伴鼻息肉的短期疗效研究[J]. 中华耳鼻咽喉头颈外科杂志, 2021, 56(10): 1035-1041. doi:10.3760/cma.j.cn115330-20210608-00338. SHEN Shen, LOU Hongfei, YAN Bing, et al. Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2021, 56(10): 1035-1041. doi:10.3760/cma.j.cn115330-20210608-00338. [64] 隋海晶, 胡艳, 陈玉迪, 等. 抗IgE单克隆抗体治疗难治性鼻窦炎伴鼻息肉三例[J]. 中华耳鼻咽喉头颈外科杂志, 2021, 56(2): 150-152. doi:10.3760/cma.j.cn115330-20201112-00864. SUI Haijing, HU Yan, CHEN Yudi, et al. Three cases of refractory sinusitis with nasal polyps treated with anti IgE monoclonal antibody[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2021, 56(2): 150-152. doi:10.3760/cma.j.cn115330-20201112-00864. [65] 隋海晶, 胡艳, 甄甄, 等. 抗IgE单克隆抗体治疗过敏性哮喘并发鼻息肉的有效性和安全性[J]. 中华临床免疫和变态反应杂志, 2021, 15(5): 505-512. doi:10.3969∕j.issn.1673-8705.2021.05.004. SUI Haijing, HU Yan, ZHEN Zhen, et al. Efficacy and safety of anti-IgE monoclonal antibody treatment for allergic asthma with nasal polyps[J]. Chinese Journal of Allergy & Clinical Immunology, 2021, 15(5): 505-512. doi:10.3969∕j.issn.1673-8705.2021.05.004. [66] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006, 118(5): 1133-1141. doi:10.1016/j.jaci.2006.05.031. [67] Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps(SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Respir Med, 2021, 9(10): 1141-1153. doi:10.1016/S2213-2600(21)00097-7. [68] Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines[J]. Allergy, 2021, 76(8): 2337-2353. doi:10.1111/all.14809. [69] Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha MAb with enhanced antibody-dependent cell-mediated cytotoxicity function[J]. J Allergy Clin Immunol, 2010, 125(6): 1344-1353.e2. doi:10.1016/j.jaci.2010.04.004. [70] Chitguppi C, Patel P, Gandler A, et al. Effect of benralizumab in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a case series[J]. Am J Rhinol Allergy, 2021, 35(5): 559-567. doi:10.1177/1945892420978351. [71] Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps(CRSwNP):a randomized double-blind placebo-controlled trial[J]. Clin Exp Allergy, 2021, 51(6): 836-844. doi:10.1111/cea.13852. [72] Lombardo N, Pelaia C, Ciriolo M, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma[J]. Int J Immunopathol Pharmacol, 2020, 34: 2058738420950851. doi:10.1177/2058738420950851. [73] Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2022, 149(4): 1309-1317.e12. doi:10.1016/j.jaci.2021.08.030. [74] Wu QW, Zhang YN, Kong WF, et al. Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis[J]. Int Arch Allergy Immunol, 2022, 183(3): 279-288. doi:10.1159/000519228. [75] Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis[J]. J Allergy Clin Immunol, 2022, 149(4): 1286-1295. doi:10.1016/j.jaci.2021.09.009. [76] Cai SR, Xu SL, Lou HF, et al. Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis[J]. J Allergy Clin Immunol Pract, 2022,(22): S2213-S2198. doi:10.1016/j.jaip.2022.02.034. [77] Wu QW, Yuan LX, Qiu HJ, et al. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials[J]. BMJ Open, 2021, 11(9): e047344. doi:10.1136/bmjopen-2020-047344. [78] O'Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial[J]. Lancet Respir Med, 2016, 4(10): 797-806. doi:10.1016/S2213-2600(16)30227-2. [79] Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial[J]. Clin Exp Allergy, 2012, 42(7): 1097-1103. doi:10.1111/j.1365-2222.2012.04014.x. [80] Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma[J]. Am J Respir Crit Care Med, 2013, 188(11): 1294-1302. doi:10.1164/rccm.201212-2318OC. [81] Chong LY, Piromchai P, Sharp S, et al. Biologics for chronic rhinosinusitis[J]. Cochrane Database Syst Rev, 2021, 3: CD013513. doi:10.1002/14651858.CD013513.pub3. [82] 王成硕, 张罗. 慢性鼻窦炎伴鼻息肉进入生物制剂治疗时代[J]. 中华耳鼻咽喉头颈外科杂志, 2021, 56(10): 1023-1027. doi:10.3760/cma.j.cn115330-20210509-00260. WANG Chengshuo, ZHANG Luo. Biologics: a new option in treatment of chronic rhinosinusitis with nasal polyps[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2021, 56(10): 1023-1027. doi:10.3760/cma.j.cn115330-20210509-00260. [83] Anderson WC III, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?[J]. Ann Allergy Asthma Immunol, 2019, 122(4): 367-372. doi:10.1016/j.anai.2019.01.018. [84] Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial[J]. J Allergy Clin Immunol, 2017, 140(4): 1024-1031.e14. doi:10.1016/j.jaci.2017.05.044. |
| [1] | AO Tian,CHENG Lei. An endotype study of chronic rhinosinusitis with nasal polyps and precise control and treatment under the guidance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 7-14. |
| [2] | SHI Shuai, ZHENG Quan,CHENG Lei. Research advances of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 36-42. |
| [3] | WANG Huan, HU Li,YU Hongmeng. Research progress of olfactory dysfunction in chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 43-49. |
| [4] | YI Ruonan,CHEN Fuquan. Eosinophils and Olfactory Dysfunction [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 50-55. |
| [5] | GU Yu, WAN Xin,XIAO Zi'an. The interaction between neutrophils and eosinophils in chronic rhinosinusitis and the implications on treatment options [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 56-63. |
| [6] | LIN Hai, ZHU Ying,ZHANG Weitian. The roles of ion channels in the pathogenesis of chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 64-70. |
| [7] | QIAO Xinjie,. Research progress on the signal transduction pathway and other factors related to epithelial-mesenchymal transformation in chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 71-77. |
| [8] | HUANG Danyi, ZHANG Ting,CHEN Jing, ZHANG Wei. Progress of research regarding the role of the epithelial barrier in chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 78-83. |
| [9] | LI Jiani, ZHU Dongdong,MENG Cuida. The role of epigenetics in the pathogenesis of chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 84-91. |
| [10] | CAO Xuan,XIAO Xuping, LI Yunqiu. Advances in the application of hyaluronic acid in chronic sinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 104-109. |
| [11] | WANG Na,CHAI Xiangbin. Research progress on prostate-derived ETS factor in asthma and inflammatory diseases of the nasal mucosa [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 136-141. |
| [12] | LIU Yitong, ZHOU Suizi,QIU Qianhui. Research progress on NLRP3 inflammasome in chronic rhinosinusitis and allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 142-146. |
| [13] | LI Lin, GAO Zhengwen, CUI Nan, SUN Jianping, HUANG Xianming, CUI Jing. Bioinformatics analysis of gene expression profile in pediatric patients with chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 171-180. |
| [14] | CHEN Shiqin, WEI Pingcun, HU Yunlong, HU Jinwang. Effects of three different nasal uses of glucocorticoid on mucosal outcome after endoscopic sinus surgery [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 195-201. |
| [15] | LIN Manqing, ZHOU Min, CHEN Tengyu, LI-Dan, FANG Caishan, WANG Ruizhi, ZHU Jinxiang, RUAN-Yan, XU Huixian, WANG Peiyuan. Meta-analysis of the efficacy and safety of traditional Chinese medicine for nasal irrigation in the treatment of chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 209-225. |
|